S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Laser breakthrough could send stock soaring 2,467% (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Laser breakthrough could send stock soaring 2,467% (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Laser breakthrough could send stock soaring 2,467% (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Laser breakthrough could send stock soaring 2,467% (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
NYSE:BHC

Bausch Health Companies (BHC) Stock Price, News & Analysis

$8.67
+0.07 (+0.81%)
(As of 02/21/2024 ET)
Today's Range
$8.57
$8.82
50-Day Range
$7.26
$8.67
52-Week Range
$5.57
$10.23
Volume
3.89 million shs
Average Volume
2.22 million shs
Market Capitalization
$3.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

Bausch Health Companies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
32.6% Upside
$11.50 Price Target
Short Interest
Bearish
5.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.66mentions of Bausch Health Companies in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1,624 Sold Last Quarter
Proj. Earnings Growth
14.41%
From $3.40 to $3.89 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.01 out of 5 stars

Medical Sector

187th out of 932 stocks

Pharmaceutical Preparations Industry

80th out of 429 stocks


BHC stock logo

About Bausch Health Companies Stock (NYSE:BHC)

Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.

BHC Stock Price History

BHC Stock News Headlines

Gold explodes past $2,000, here's what's next
After what feels like nearly a decade of disappointing returns, gold is entering a new bull market. You can get started today for just $5.
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Bausch Health Companies (BHC) Set to Announce Earnings on Thursday
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
See More Headlines
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/02/2021
Today
2/22/2024
Next Earnings (Confirmed)
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
19,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.50
High Stock Price Target
$14.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+32.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-225,000,000.00
Pretax Margin
-8.66%

Debt

Sales & Book Value

Annual Sales
$8.12 billion
Cash Flow
$7.35 per share
Book Value
$0.72 per share

Miscellaneous

Free Float
334,638,000
Market Cap
$3.13 billion
Optionable
Optionable
Beta
0.79
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Thomas J. Appio (Age 62)
    CEO & Director
    Comp: $4.73M
  • Ms. Seana  CarsonMs. Seana Carson (Age 52)
    Executive VP & General Counsel
    Comp: $720.5k
  • Mr. John S. Barresi (Age 51)
    Senior VP, Controller, Chief Accounting Officer & Interim CFO
  • Mr. Mirza Dautbegovic
    Senior VP & COO
  • Mr. Josh Coyle
    Senior Vice President of Sales & Salix
  • Ms. Kathleen Fitzpatrick
    Senior VP & Chief HR Officer
  • Dr. Tage Ramakrishna M.D. (Age 50)
    Chief Medical Officer and President of R&D
  • Mr. Jeff Hartness
    Executive VP of Market Access, Commercial Operations, Neurology, Generics & Government Affairs
  • Dr. Graham Jackson
    Senior VP & Chief Quality Officer
  • Mr. Cees Heiman
    Senior Vice President of Europe & Canada














BHC Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings
or view top-rated stocks.

What is Bausch Health Companies' stock price target for 2024?

3 brokers have issued 1-year price objectives for Bausch Health Companies' shares. Their BHC share price targets range from $9.00 to $14.00. On average, they expect the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price.
View analysts price targets for BHC
or view top-rated stocks among Wall Street analysts.

How have BHC shares performed in 2024?

Bausch Health Companies' stock was trading at $8.02 at the beginning of the year. Since then, BHC shares have increased by 8.1% and is now trading at $8.67.
View the best growth stocks for 2024 here
.

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our BHC earnings forecast
.

How can I listen to Bausch Health Companies' earnings call?

Bausch Health Companies will be holding an earnings conference call on Thursday, February 22nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) issued its earnings results on Monday, August, 2nd. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.95 by $0.02. The company earned $2.10 billion during the quarter, compared to analyst estimates of $2.12 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 1,124.72% and a negative net margin of 11.27%.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include National Bank of Canada FI (4.34%), Nomura Holdings Inc. (3.68%), Healthcare of Ontario Pension Plan Trust Fund (3.60%), Royal Bank of Canada (3.25%), Vanguard Group Inc. (3.21%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson and Steven D Miller.
View institutional ownership trends
.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BHC) was last updated on 2/22/2024 by MarketBeat.com Staff